Which of these has no role in treatment of dangerous hyperkalemia?
**Core Concept**
The management of hyperkalemia involves stabilizing cardiac membranes, shifting potassium into cells, and removing excess potassium from the body. In the context of dangerous hyperkalemia, treatment aims to rapidly correct life-threatening cardiac arrhythmias and stabilize cardiac function.
**Why the Correct Answer is Right**
In the treatment of dangerous hyperkalemia, insulin and glucose are administered together to drive potassium into cells. This is based on the principle that insulin facilitates the uptake of potassium into cells by activating the sodium-potassium pump. Calcium gluconate is given to stabilize cardiac membranes and prevent arrhythmias by antagonizing the effects of potassium on cardiac cells. The use of beta-2 agonists, such as albuterol, helps to shift potassium into cells and is often used in conjunction with the other treatments.
**Why Each Wrong Option is Incorrect**
**Option A:** Calcium gluconate is an essential component of treating dangerous hyperkalemia, as it helps to stabilize cardiac membranes and prevent arrhythmias.
**Option B:** Beta-2 agonists, such as albuterol, play a crucial role in the treatment of hyperkalemia, as they help to shift potassium into cells.
**Option C:** Sodium polystyrene sulfonate (Kayexalate) is used to remove excess potassium from the body, making it an effective treatment for hyperkalemia.
**Clinical Pearl / High-Yield Fact**
Insulin and glucose should be administered together to drive potassium into cells, as insulin alone does not effectively lower potassium levels in the absence of glucose.
**Correct Answer: D.**